More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.
DUBLIN, Ohio, December 9, 2021 — More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes. These findings were released today in the latest edition of Oncology Insights, a report published by Cardinal Health Specialty Solutions based on surveys with more than 240 US oncologists.
Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most frequently in their patients, but personality and addiction disorders were also mentioned. Despite the high prevalence of mental health concerns, only a third of the surveyed oncologists said they frequently refer patients for mental health treatment and nearly half say there are not adequate resources available to support the mental health needs of cancer patients.
"Recent research indicates that mental health generally has declined since the start of the COVID-19 pandemic. This is particularly concerning for patients with cancer who are already at an increased risk for mental health distress," said Heidi Hunter, president of Cardinal Health Specialty Solutions. "Our latest oncology survey shines a light on this issue and provides insights on additional education and resources that could help oncologists to provide much-needed support to patients."
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More